Assessment of the Efficacy Safety and Pharmacokinetics of Orally Administered Epetraborole in Patients with Treatment-refractory Mycobacterium avium Complex Lung Disease

Go Back to All Clinical Trials

Assessment of the Efficacy Safety and Pharmacokinetics of Orally Administered Epetraborole in Patients with Treatment-refractory Mycobacterium avium Complex Lung Disease

Brief description of study

The purpose of this study is to learn about the effects of a study medicine, Epetraborole, to assess the efficacy for treating refractory MAC, to see how safe Epetraborole is for patients with refractory MAC, to confirm the dosage, to understand how Epetraborole leaves the body, and to assess how patients feel while taking the study drug. The sponsor will also compare the effects of the study medicine, Epetraborole plus optimized background regimen, (OBR), with placebo plus OBR to find out which is better for treating MAC.

Clinical Study Identifier: s22-00181

ClinicalTrials.gov Identifier: NCT05327803

Principal Investigator: Doreen J Addrizzo-Harris.

Other Investigator: Tejas Shah.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies